Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Harper Hubbeling"'
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Beow Y. Yeap, Jochen K. Lennerz, Harper Hubbeling, Rebecca J. Nagy, Jennifer Ackil, Jessica J. Lin, Marguerite Rooney, Aaron N. Hata, Emily Chin, Anna F. Farago, Alice T. Shaw, Justin F. Gainor, Richard B. Lanman, Ibiayi Dagogo-Jack
Publikováno v:
Clinical Cancer Research. 25:6662-6670
Purpose: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here, we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generatio
Autor:
Alice T. Shaw, Luc Friboulet, Daria Timonina, Benjamin J. Burke, Krystina E. Kattermann, Justin F. Gainor, Jeffrey A. Engelman, Amanda K. Riley, A. John Iafrate, Jochen K. Lennerz, Adam Langenbucher, Sergei Timofeevski, Aaron N. Hata, Leila Dardaei, Cyril H. Benes, Lorin A. Ferris, Jessica J. Lin, Kylie Prutisto-Chang, Ted William Johnson, Harper Hubbeling, Rebecca S. Heist, Ibiayi Dagogo-Jack, Mari Mino-Kenudson, Satoshi Yoda, Michael S. Lawrence
Publikováno v:
Cancer Discovery
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed pr